search
Back to results

Routine Versus Selective Intraoperative ECMO in Lung Transplant

Primary Purpose

Lung Transplant; Complications, Extracorporeal Circulation; Complications, Postoperative Complications

Status
Active
Phase
Not Applicable
Locations
Canada
Study Type
Interventional
Intervention
Routine ECMO
On demand ECMO
Sponsored by
Centre hospitalier de l'Université de Montréal (CHUM)
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Lung Transplant; Complications

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

Patients undergoing lung transplant surgery during the study period (6 months)

Exclusion Criteria:

  1. Inability to provide consent for the study or patient refusal
  2. Retransplantation
  3. Multi-organ transplantation
  4. Lung transplant recipients where intraoperative support is mandatory and "off- pump" transplant would be unsafe:

    a. Severe pulmonary hypertension (PH):

    i. Systolic pulmonary artery pressure (PAP) ≥ 80 mm Hg on echocardiography, right heart catheterization, or pulmonary artery catheter measurement

    ii. Mean PAP ≥ 55 mm Hg on echocardiography, right heart catheterization, or pulmonary artery catheter measurement

    iii. The ratio of mean pulmonary to systemic artery pressure of more than 0.66

    b. Moderate to severe right ventricular (RV) hypokinesis or dysfunction

    c. Left ventricular dysfunction: Defined as ejection fraction (LVEF) < 50% on echocardiography, ventriculography, computed tomography (CT), or magnetic resonance imaging (MRI)

    d. Significant coronary artery disease (CAD)requiring stenting or surgical grafting

Sites / Locations

  • Centre Hospitalier de l'Université de Montréal

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

On demand ECMO (study group)

Routine ECMO (control group)

Arm Description

Outcomes

Primary Outcome Measures

Study recruitment rate

Secondary Outcome Measures

Percentage of patients loss to follow-up
The composite incidence of death, disabling stroke, grade 2 or 3 primary graft dysfunction at 72 hours, major bleeding (BARC grade 3a, 3b or 5), vascular complications, or stage II or III acute kidney injury at 14 days.
Incidence of all-cause mortality at 30 days, 90 days, and one year
Incidence of postoperative stroke / cerebrovascular accident
Incidence of an Early major postoperative neurologic complication (EMPNC): This includes stroke, severe encephalopathy, and severe seizures diagnosed within 14 days after surgery.
Incidence of severe postoperative complications. This is defined as Clavien-Dindo grade III complication or greater

Full Information

First Posted
August 9, 2022
Last Updated
April 12, 2023
Sponsor
Centre hospitalier de l'Université de Montréal (CHUM)
search

1. Study Identification

Unique Protocol Identification Number
NCT05505422
Brief Title
Routine Versus Selective Intraoperative ECMO in Lung Transplant
Official Title
Randomized Trial of Routine Versus Selective Use of Intraoperative Extracorporeal Mechanical Support During Lung Transplantation : a Pilot Study
Study Type
Interventional

2. Study Status

Record Verification Date
April 2023
Overall Recruitment Status
Active, not recruiting
Study Start Date
September 15, 2022 (Actual)
Primary Completion Date
March 15, 2023 (Actual)
Study Completion Date
March 15, 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Centre hospitalier de l'Université de Montréal (CHUM)

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Intraoperative hemodynamic management is vital in the success of lung transplantation. Significant intraoperative hemodynamic compromise and hypoxic episodes may contribute to an increase in severe postoperative complications related to hypoperfusion, including cerebrovascular accidents, acute kidney injury, and mesenteric ischemia. In certain lung transplant recipients, intraoperative cardiopulmonary support is mandatory because certain factors would make "off-pump" transplants unsafe. These include severe pulmonary hypertension or severe ventricular dysfunction. In such patients, routine intraoperative support should be employed. However, it is possible to conduct the lung transplant without cardiopulmonary support in the remainder of patients who do not have severe pulmonary hypertension or right heart dysfunction. In such patients, the lung transplant may be started without cardiopulmonary support. However, cardiopulmonary support may be initiated "on-demand" if there is development or impending hemodynamic embarrassment or hypoxia. Conversely, the opposite approach would be to routinely conduct all lung transplant operations using cardiopulmonary support, which may also lead to specific ECMO-related complications. The investigators question whether on demand intraoperative ECMO in patients with significant risk factors will produce severe postoperative complications in a rate similar to routine ECMO.
Detailed Description
Hypothesis: In patients where cardiopulmonary bypass (CPB) / ECMO is not mandatory, on-demand use of intra-operative ECMO is equivalent to routine use for patients undergoing lung transplant. The study will be a prospective, randomized controlled trial. The investigators seek to compare outcomes of two different strategies of cardiopulmonary support during lung transplantation; routine support with ECMO versus selective (on-demand), indication- based support with ECMO. The allocation ratio will be 1:1. A multi-center trial is necessary to allow for a sufficient sample size. However, the investigators believe a pilot study is essential to determine feasibility before embarking on such a significant undertaking. In this preliminary pilot study, recruitment will be limited to lung transplant patients at the Centre hospitalier de l'Universite de Montreal (CHUM). The primary purpose of the pilot study will be to define recruitment ability and assess the feasibility of conducting the study. Depending on the results of this pilot study, the next step would be to expand the study to multiple lung transplant centers to achieve an adequate sample size and power, allowing the investigators to answer the question of interest.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Lung Transplant; Complications, Extracorporeal Circulation; Complications, Postoperative Complications

7. Study Design

Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
29 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
On demand ECMO (study group)
Arm Type
Experimental
Arm Title
Routine ECMO (control group)
Arm Type
Active Comparator
Intervention Type
Device
Intervention Name(s)
Routine ECMO
Intervention Description
Routine ECMO during lung tansplant
Intervention Type
Device
Intervention Name(s)
On demand ECMO
Intervention Description
Selective, indication-based intraoperative cardiopulmonary support. In this group, the transplant will be planned without cardiopulmonary support. intraoperative ECMO will be used selectively based on hemodynamic and/or gas exchange abnormalities : Inability to maintain adequate hemodynamics and stable perfusion or oxygenation during surgery Prolonged high dose pressor required to maintain adequate perfusion A sustained drop in cerebral saturation > 25% of baseline despite initial attempts at optimization Inability to tolerate pulmonary artery clamping Inadequate gas exchange despite attempts at the optimization of ventilator parameters and treatments related to respiratory mechanics and ventilation/perfusion matching Inadequate exposure to the surgical field
Primary Outcome Measure Information:
Title
Study recruitment rate
Time Frame
6 months after the onset of study
Secondary Outcome Measure Information:
Title
Percentage of patients loss to follow-up
Time Frame
1 year
Title
The composite incidence of death, disabling stroke, grade 2 or 3 primary graft dysfunction at 72 hours, major bleeding (BARC grade 3a, 3b or 5), vascular complications, or stage II or III acute kidney injury at 14 days.
Time Frame
14 days
Title
Incidence of all-cause mortality at 30 days, 90 days, and one year
Time Frame
1 year
Title
Incidence of postoperative stroke / cerebrovascular accident
Time Frame
14 days
Title
Incidence of an Early major postoperative neurologic complication (EMPNC): This includes stroke, severe encephalopathy, and severe seizures diagnosed within 14 days after surgery.
Time Frame
14 days
Title
Incidence of severe postoperative complications. This is defined as Clavien-Dindo grade III complication or greater
Time Frame
14 days
Other Pre-specified Outcome Measures:
Title
Incidence and grade of primary graft dysfunction (PGD) at 0, 24, 48, and 72 hours
Time Frame
From the end of surgery up to 72 hours after surgery
Title
Incidence of postoperative bleeding complications. The definition of bleeding complication is based on Bleeding Academic Research Consortium (BARC) classification
Time Frame
14 days after surgery
Title
Intraoperative blood product transfusion requirements
Time Frame
From the beginning of surgery to transfer to the intensive care unit
Title
Perioperative blood product transfusion requirements
Description
From the beginning of surgery to 14 days after surgery, including return to the operating room for subsequent surgeries
Time Frame
14 days
Title
Intensive care unit and hospital length of stay in days
Time Frame
Beginning from the arrival to the intensive care unit immediately after surgery
Title
Duration of mechanical ventilation in hours
Description
BiPAP and CPAP are not considered mechanical ventilation. Tracheostomy is not considered mechanical ventilation if a ventilator is not needed.
Time Frame
Beginning from the arrival to the intensive care unit immediately after surgery, up to about 30 days
Title
Incidence of re-intubation
Time Frame
14 days
Title
Incidence of postoperative tracheostomy
Time Frame
21 days
Title
Incidence of acute kidney injury (AKI) within 14 days. The definition of AKI is based on Kidney Disease; improving global outcomes (KDIGO) classification
Time Frame
14 days
Title
Incidence of vascular complications
Time Frame
14 days
Title
Forced expiratory volume at 1 second (FEV1) at 1 year
Time Frame
1 year
Title
Incidence of stroke
Time Frame
1 year
Title
Incidence of acute rejection episodes
Time Frame
1 year

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patients undergoing lung transplant surgery during the study period (6 months) Exclusion Criteria: Inability to provide consent for the study or patient refusal Retransplantation Multi-organ transplantation Lung transplant recipients where intraoperative support is mandatory and "off- pump" transplant would be unsafe: a. Severe pulmonary hypertension (PH): i. Systolic pulmonary artery pressure (PAP) ≥ 80 mm Hg on echocardiography, right heart catheterization, or pulmonary artery catheter measurement ii. Mean PAP ≥ 55 mm Hg on echocardiography, right heart catheterization, or pulmonary artery catheter measurement iii. The ratio of mean pulmonary to systemic artery pressure of more than 0.66 b. Moderate to severe right ventricular (RV) hypokinesis or dysfunction c. Left ventricular dysfunction: Defined as ejection fraction (LVEF) < 50% on echocardiography, ventriculography, computed tomography (CT), or magnetic resonance imaging (MRI) d. Significant coronary artery disease (CAD)requiring stenting or surgical grafting
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Basil Nasir, MD
Organizational Affiliation
Centre hospitalier de l'Université de Montréal (CHUM)
Official's Role
Principal Investigator
Facility Information:
Facility Name
Centre Hospitalier de l'Université de Montréal
City
Montreal
State/Province
Quebec
ZIP/Postal Code
H2X3E4
Country
Canada

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Routine Versus Selective Intraoperative ECMO in Lung Transplant

We'll reach out to this number within 24 hrs